Journal
NEURO-ONCOLOGY PRACTICE
Volume 4, Issue 4, Pages 201-208Publisher
OXFORD UNIV PRESS
DOI: 10.1093/nop/npw034
Keywords
clinical trial; endpoints; glioma; Neuro-oncology
Categories
Ask authors/readers for more resources
Malignant glioma represents a diverse set of molecularly heterogeneous diseases. Few therapeutic agents have been approved despite decades of clinical trials research and pre-clinical investigation. Attempts to refine neuroimaging criteria and recent discovery of the genomic profiles linking tumor subsets to survival outcomes have spurred discussion on a variety of new approaches in clinical trial design and relevant endpoints. Here we focus on those endpoints in clinical trial design for patients with primary glioma and related issues still to be resolved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available